GlassScriptPhysician profile
Amana Nasir
NPI 1306050273
$110,528.75
in general payments reported to CMS, 2019-2025
29 companies · $31K in 2025
The $31K reported for 2025 was more than what 98% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $1,164 · 2021: $1,764 · 2022: $1,019 · 2023: $24K · 2024: $51K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Honoraria: $11K · Consulting Fee: $7,644 · Food and Beverage: $4,990 · Travel and Lodging: $4,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,998.66 |
| Honoraria | $10,750.00 |
| Consulting Fee | $7,644.00 |
| Food and Beverage | $4,989.73 |
| Travel and Lodging | $4,839.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $62,141.28 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $28,572.72 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $16,784.95 | 2019-2025 | Sucraid, Sucraid |
| Mirum Pharmaceuticals, INC. | $372.16 | 2022-2025 | Livmarli, Cholbam, Chenodal |
| Takeda Pharmaceuticals U.S.A., INC. | $314.68 | 2021-2025 | Gattex, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $304.10 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $302.80 | 2023-2025 | Bylvay |
| Nestle Healthcare Nutrition INC. | $214.08 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $189.88 | 2019-2023 | |
| Abbvie INC. | $169.70 | 2019-2023 | |
| Sandoz INC. | $138.81 | 2023-2024 | Hyrimoz |
| Shockwave Medical, INC | $135.72 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Ironwood Pharmaceuticals, INC | $108.03 | 2024 | |
| Glaxosmithkline, LLC. | $104.13 | 2019-2022 | |
| Travere Therapeutics, INC. | $100.89 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $92.40 | 2022 | |
| Capsovision, INC. | $66.48 | 2023-2024 | Capsocam Plus |
| Alexion Pharmaceuticals, INC. | $63.12 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $58.73 | 2019-2022 | |
| Evoendo, INC | $50.59 | 2025 | |
| Neuraxis, INC. | $47.96 | 2022 | |
| Horizon Therapeutics Plc | $38.62 | 2019 | |
| Albireo Pharma, INC. | $37.94 | 2022 | |
| Intrabio INC | $25.24 | 2025 | Aqneursa |
| Acadia Pharmaceuticals INC | $24.59 | 2025 | Daybue |
| Azurity Pharmaceuticals, INC. | $20.74 | 2020 | |
| Phadia US INC. | $18.42 | 2024 | Immunocap |
| Pfizer INC. | $16.63 | 2023 | |
| Medtronic, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amana Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.